Table 2.
Clinical Correlations with HGF Expression in HNSCC Tumors or Serum.
| Clinicopathological Correlations with Elevated Serum/Tumoral HGF | HNSCC Sample Site/Size | Reference |
|---|---|---|
| Elevated serum HGF correlates with cancer burden | Oral Cavity (n = 31) | Uchida 2001 (ref. [86]) |
| Elevated tumoral HGF correlates with metastasis | ||
| Elevated tumoral HGF correlates with lymph node metastasis and pathologic stage | Hypopharynx (n = 40) | Kim 2006 (ref. [72]) |
| Elevated serum HGF correlates with higher tumor staging | Oral Cavity (n = 22) | Kim 2007 (ref. [84]) |
| Larynx (n = 21) | ||
| Oropharynx (n = 16) | ||
| Hypopharynx (n = 14) | ||
| Maxilla (n = 5) | ||
| Longitudinal increases of serum HGF correlate with decreased cause-specific survival | Oropharynx (n = 30) | Allen 2007 (ref. [85]) |
Clinical studies were identified by a literature search using the keywords HGF, clinicopathological correlations, HNSCC. Studies presented in the table were selected based on results with a p value <0.05.